Pay in 4 interest-free payments of $6.31 Learn more
Ships within 48 hours · Estimated delivery Aug 23 - Aug 28
Prescribe SGLT2 inhibitors, GLP-1 receptor agonists as early as possible for CV benefit Adults with type 2 diabetes assigned an SGLT2 inhibitor or a GLP-1 receptor agonist during cardiovascular outcomes trials derived benefit from the therapies regardless of whether they were prescribed insulin, according to a meta-analysis
Overall, the multimorbidity of depression and T2DM involves shared genetic risk factors and multiple underlying biological mechanisms, including HPA axis dysregulation, pro-inflammatory states, gut-brain axis interactions, and insulin signaling alterations, which can affect neurotransmission
AIM Patient
456 Until May 2023, the drug was formally approved by the FDA from Emergency Use Authorization (EUA)
